Join us to hear Life Technologies Senior Scientist Susan Magdaleno, PhD, present this free seminar: RNAi: siRNA screening & how to get the most bang for your buck

Wednesday, December 12, 2012 University of Louisville, CTRB Room 124

9:30–11:00 a.m.

Scientist-to-scientist seminar

11:00–11:30 a.m.

Lunch (provided by Life Technologies)

11:30–1:00 p.m.

Customer data seminar

1:00 p.m. Tour of the screening facility on the 6th fl oor of the CTRB

Susan Magdaleno, PhD, is an R&D senior scientist for Life Technologies, in Austin, TX. She leads the research and development of multiple Ambion® RNA products. A scientist at Life Technologies since 2005, Dr. Magdaleno has developed multiple product lines in RNA analysis, including siRNA, miRNA, and RNA delivery reagents. Currently, she is focused on creating nextgeneration tools for the analysis of all RNA types, improved methods for extracting RNA from clinical samples, and the characterization of RNA from exosomes.

Register for this free seminar to learn about the relevance of siRNA technology for screening as opposed to shRNA-based technology. The seminar will also highlight the value proposition of the Silencer® and Silencer® Select siRNA technologiesfor advancing phenotype-based HT screening and higher hit rate for drug discovery (low false positives and false negatives).

Abstract
9:30–11:00 a.m.

Silencer® Select siRNAs: Combining novel siRNA design and LNA® chemical modifi cation for enhanced specifi city without compromising performance

Target identifi cation through genome-wide RNAi screening is rapidly becoming a household tool in major academic and pharmaceutical institutions. The progress of discovery has been hampered by poor siRNA design and off-target effects found in first and second generation siRNA technologies. By combining novel criteria for siRNA prediction with locked nucleic acid (LNA®) chemical modifi cations of the siRNA backbone, Life Technologies has developed Silencer® Select siRNAs, a third-generation genome-wide siRNA collection that displays superior knock-down of target mRNA with minimal off-target effects. siRNA features and knockdown potential was analyzed from over 2300, siRNA sequences and used to develop a novel algorithm based on support vector machine (SVM) strategies for siRNA design. siRNA predicted using the novel algorithm demonstrated statistically improved prediction power and yielded greater than 94% effi cacy at predicting hyperpotent siRNAs. Additionally, novel bioinformatic filters have been developed to identify the most specific siRNAs with respect to cytotoxicity, miRNA natural seed region sequences and infl ammatory nucleotide motifs. Extensive optimization of LNA® modifi cation placement within the siRNA was performed to determine which positions in the siRNA duplex were most effi cient at improving siRNA specifi city as measured by siRNA strand bias, microarray global gene profi ling, and cell-based, high-content analysis. Optimized LNA® chemical modifi cation combined with hyperpotent siRNA design provides a platform to conduct RNAi screens with 5–50-fold lower fi nal siRNA concentrations, which in turn, reduces screening costs from delivery agents and false-positive hit follow-up experiments. We will share highlights from the chemical modifi cation optimization and siRNA performance comparisons between unmodifi ed siRNAs, siRNA modifi ed with 2’O Me, and LNA®-modified siRNA in multiple assays and siRNA screening experiments.

Customer data seminar
11:30–1:00 p.m.

Questions? Contact Alicia Camper at alicia.camper@lifetech.com

Register Now